D Bossé1, M Vickers2, F Lemay3, A Beaudoin3. 1. Department of Medicine, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC; 2. Ottawa Regional Cancer Centre, Ottawa, ON; 3. Gastroenterology Division, Department of Medicine, Centre hospitalier universitaire de Sherbrooke and Centre de recherche clinique Étienne-Le Bel, Sherbrooke, QC.
Abstract
BACKGROUND: Metastatic colorectal cancer (mcrc) commonly affects elderly people, an understudied subset of patients. We analyzed the survival impact of the first and subsequent lines of chemotherapy in eligible non-trial patients 70 years of age and older with mcrc treated between 2004 and 2012. METHODS: This single-centre retrospective analysis estimated overall survival (os) and progression-free survival (pfs) using the Kaplan-Meier method. Multivariate analysis was used to adjust for age, sex, Eastern Cooperative Oncology Group performance status, score on the Charlson comorbidity index, dependency in activities of daily living, and exposure to 1 or more chemotherapy doublets, capecitabine alone, or best supportive care (bsc). RESULTS: Of 109 patients identified, 29 elected bsc, and 80 received chemotherapy. In multivariate analysis, age was not associated with os [hazard ratio (hr): 0.99; 95% confidence interval (ci): 0.92 to 1.05], but a performance status of 2 or higher was associated with a decreased likelihood of survival (hr: 3.12; 95% ci: 1.87 to 5.76), and exposure to 1 or more doublets was associated with improved survival (hr: 0.33; 95% ci: 0.17 to 0.66). In univariate analysis, a trend toward improved os was observed for first-line doublet chemotherapy compared with capecitabine (hr: 0.66; 95% ci: 0.41 to 1.07), and pfs was superior (hr: 0.46; 95% ci: 0.26 to 0.84). Compared with exposure to 1 doublet, exposure to the 3 potential cytotoxic chemotherapies was not associated with improved os (hr: 0.77; 95% ci: 0.41 to 1.43). The incidence of neutropenia with first-line folfiri was 40%; the incidences of bevacizumab-related arterial and venous thrombosis were both 8%. CONCLUSIONS: Exposure to 1 or more doublet chemotherapies for mcrc was associated with better outcomes in non-trial patients 70 years of age and older. Elderly patients treated with palliative chemotherapy and bevacizumab should be monitored carefully for arterial and venous thrombotic events.
BACKGROUND:Metastatic colorectal cancer (mcrc) commonly affects elderly people, an understudied subset of patients. We analyzed the survival impact of the first and subsequent lines of chemotherapy in eligible non-trial patients 70 years of age and older with mcrc treated between 2004 and 2012. METHODS: This single-centre retrospective analysis estimated overall survival (os) and progression-free survival (pfs) using the Kaplan-Meier method. Multivariate analysis was used to adjust for age, sex, Eastern Cooperative Oncology Group performance status, score on the Charlson comorbidity index, dependency in activities of daily living, and exposure to 1 or more chemotherapy doublets, capecitabine alone, or best supportive care (bsc). RESULTS: Of 109 patients identified, 29 elected bsc, and 80 received chemotherapy. In multivariate analysis, age was not associated with os [hazard ratio (hr): 0.99; 95% confidence interval (ci): 0.92 to 1.05], but a performance status of 2 or higher was associated with a decreased likelihood of survival (hr: 3.12; 95% ci: 1.87 to 5.76), and exposure to 1 or more doublets was associated with improved survival (hr: 0.33; 95% ci: 0.17 to 0.66). In univariate analysis, a trend toward improved os was observed for first-line doublet chemotherapy compared with capecitabine (hr: 0.66; 95% ci: 0.41 to 1.07), and pfs was superior (hr: 0.46; 95% ci: 0.26 to 0.84). Compared with exposure to 1 doublet, exposure to the 3 potential cytotoxic chemotherapies was not associated with improved os (hr: 0.77; 95% ci: 0.41 to 1.43). The incidence of neutropenia with first-line folfiri was 40%; the incidences of bevacizumab-related arterial and venous thrombosis were both 8%. CONCLUSIONS: Exposure to 1 or more doublet chemotherapies for mcrc was associated with better outcomes in non-trial patients 70 years of age and older. Elderly patients treated with palliative chemotherapy and bevacizumab should be monitored carefully for arterial and venous thrombotic events.
Authors: Ab A Aaldriks; Lydia G M van der Geest; Erik J Giltay; Saskia le Cessie; Johanneke E A Portielje; Bea C Tanis; Johan W R Nortier; Ed Maartense Journal: J Geriatr Oncol Date: 2013-04-30 Impact factor: 3.599
Authors: T J Price; D Zannino; K Wilson; R J Simes; J Cassidy; G A Van Hazel; B A Robinson; A Broad; V Ganju; S P Ackland; N C Tebbutt Journal: Ann Oncol Date: 2011-10-29 Impact factor: 32.976
Authors: Howard S Hochster; Lowell L Hart; Ramesh K Ramanathan; Barrett H Childs; John D Hainsworth; Allen L Cohn; Lucas Wong; Louis Fehrenbacher; Yousif Abubakr; M Wasif Saif; Lee Schwartzberg; Eric Hedrick Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Supriya G Mohile; Molly Hardt; William Tew; Cynthia Owusu; Heidi Klepin; Cary Gross; Ajeet Gajra; Stuart M Lichtman; Tao Feng; Kayo Togawa; Rupal Ramani; Vani Katheria; Kurt Hansen; Arti Hurria Journal: Oncologist Date: 2013-04-10
Authors: Mark Kozloff; Marianne Ulcickas Yood; Jordan Berlin; Patrick J Flynn; Fairooz F Kabbinavar; David M Purdie; Mark A Ashby; Wei Dong; Mary M Sugrue; Axel Grothey Journal: Oncologist Date: 2009-09-02
Authors: Matthew T Seymour; Lindsay C Thompson; Harpreet S Wasan; Gary Middleton; Alison E Brewster; Stephen F Shepherd; M Sinead O'Mahony; Timothy S Maughan; Mahesh Parmar; Ruth E Langley Journal: Lancet Date: 2011-05-11 Impact factor: 79.321
Authors: James Cassidy; Leonard B Saltz; Bruce J Giantonio; Fairooz F Kabbinavar; Herbert I Hurwitz; Ulrich-Peter Rohr Journal: J Cancer Res Clin Oncol Date: 2009-11-11 Impact factor: 4.553
Authors: Michiel W H van Beek; Monique Roukens; Wilco C H Jacobs; Johanna N H Timmer-Bonte; Cees Kramers Journal: Drugs Real World Outcomes Date: 2018-09